KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene.
Melyssa S RobertsLindsey J AnstineViviane S FinkeBenjamin L BrysonBryan M WebbKristen L Weber-BonkDarcie D SeachristParth R MajmudarRuth A KeriPublished in: Breast cancer research : BCR (2020)
KLF4 is a major regulator of the efficacy of EGFR inhibitors in TNBC cells that may underlie the variable effectiveness of such drugs in patients.
Keyphrases
- epidermal growth factor receptor
- tyrosine kinase
- advanced non small cell lung cancer
- end stage renal disease
- transcription factor
- breast cancer cells
- small cell lung cancer
- induced apoptosis
- ejection fraction
- randomized controlled trial
- newly diagnosed
- chronic kidney disease
- systematic review
- prognostic factors
- peritoneal dialysis
- cell cycle arrest
- genome wide
- gene expression
- dna methylation
- endoplasmic reticulum stress
- signaling pathway
- pi k akt